Sign inJoin waitlistJoin the waitlist

MM

Michael Mauro

Attending Physician · New York Presbyterian Hospital

Credentials: · · · · ·

History

Memorial Sloan Kettering Bergen
2019–Present

New York Presbyterian Hospital
1997–1998
New York Presbyterian Hospital
1994–1997
Geisel School of Medicine at Dartmouth
1990–1994

Research

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the…
European Journal of Heart Failure · 2020 · 646 citations
Ponatinib in refractory Philadelphia chromosome-positive leukemias
New England Journal of Medicine · 2012 · 609 citations
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
New England Journal of Medicine · 2016 · 392 citations

Jorge Cortes
52 papers
Michael Deininger
32 papers
Brian Druker
23 papers
Jerald Radich
19 papers
Neil Shah
16 papers
MT
Moshe Talpaz
14 papers
Hagop Kantarjian
13 papers
Javier Pinilla-Ibarz
12 papers
Daniel DeAngelo
11 papers
Ehab Atallah
10 papers
KS
Koji Sasaki
10 papers
MH
Michael Heinrich
10 papers

Grants

OHSU Knight Cancer Institute
National Cancer Institute · P30
Project lead · $390.5K · Oregon Health & Science University
2005–2010

Clinical trials

Imatinib Mesylate in Treating Patients With Myelofibrosis
Principal investigator · Terminated · Phase 2
OHSU Knight Cancer Institute
2005–2011
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Principal investigator · Completed · Phase 1, Phase 2
OHSU Knight Cancer Institute
2002–2005
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Study chair · Recruiting · Phase 2
Medical College of Wisconsin
2021–2029
Asciminib Roll-over Study
Site PI · Recruiting · Phase 4
Novartis Pharmaceuticals
2022–2030